A Randomized, Clinical Study to evaluate the Efficacy and Safety of Safoof-i-Ushba and Roghan-i-Banafsha in Taqashshur al-Jild(Psoriasis)

Phase 2

Not yet recruiting

• Conditions: Other psoriasis,

• Registration Number: CTRI/2023/03/050418
• Lead Sponsor: National Research Institute of Unani Medicine for Skin Disorders

Brief Summary

Psoriasis is a papulo-squamous disorder of the skin characterized by sharply defined red scaly lesion. They vary in size from pin point to large plaques. It is universal in occurrence and the incidence is 1 to 3 % of the world’s population. A family history is found in 300% of the patient. Taqashshur al-Jild is also defined as a type ofskin disease characterized by roughening and hardening of affected part of skin accompanied with sloughing of fish like scales and itching. Unani system of medicine is based on Humoral concept. According to this concept: psoriasis is a melancholic disorder caused by derangement of Khilṭ-i Sawda (morbid black bile) resulting from Ḥiddat and Taʻaffun-i Dam (impure blood). Taqashshur al-Jild (Psoriasis) is still incurable, Unani formulations, Safūf-I Ushba possesses Muṣaffī-i Dam (blood purifier) and Munzij wa Mush’il-i Sawda (concoctive and purgative of melancholic humor) and removal of bad humors actions, and Rogan i-Banafsha possesses soothing

actions, resolvent, sedative effects. After completion of the study, data obtained will be analyzed statistically by using an appropriate t  test to evaluate the significance of results. p<0.05 will be considered significant.

Detailed Description

Not available

Study Timeline

• Last Update Posted: 2023-03-03
• Study Start: 2023-10-03

Recruitment & Eligibility

• Status: Not Yet Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Patient clinically stable.
• Patient with clinically diagnosed Taqashshur al-jild (psoriasis) of plaque type.
• Psoriasis area severity index (PASI) ≥10%.

Exclusion Criteria

• Participants aged <18and >60years 2.
• Known cases of significant Pulmonary/Cardiovascular/ Hepato-renal Dysfunction, Malignancy, HIV infection, AIDS, etc.
• Erythrodermic psoriasis.
• Pregnancy and Lactation.
• Patient not willing to attend treatment regularly.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. Reduction in Psoriasis Area Severity Index (PASI)	12 weeks
2. Improvement in Investigators Global Assessment (IGA)	12 weeks
3. Improvement in Patient’s Global Assessment (PGA) on VAS	12 weeks

Secondary Outcome Measures

Name	Time	Method
Systemic Safety Assessment	12 weeks

Trial Locations

Locations (1)

National Research Institute of Unani Medicine for Skin Disorders; 🇮🇳 Hyderabad, TELANGANA, India

National Research Institute of Unani Medicine for Skin Disorders

🇮🇳Hyderabad, TELANGANA, India

Abdur Rahman Khan

Principal investigator

8574664018

a.rahmanbums12@gmail.com